Anaplastic Lymphoma Kinase Inhibitor Development: Enhanced Delivery to the Central Nervous System

Overview

Journal Transl Lung Cancer Res

Date 2023 Sep 11

PMID 37691872

Authors

Toyoaki Hida

Affiliations

Soon will be listed here.

Citing Articles

Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase () rearrangements and co-existing alterations-a retrospective cohort study.

Li J, Huang K, Ji H, Qian J, Lu H, Zhang Y Transl Lung Cancer Res. 2024; 12(12):2505-2519.

PMID: 38205204 PMC: 10775000. DOI: 10.21037/tlcr-23-658.

References

Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L . P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2016; 3:54-66. PMC: 4739423. DOI: 10.1016/j.ebiom.2015.12.009. View

Abbott N, Patabendige A, Dolman D, Yusof S, Begley D . Structure and function of the blood-brain barrier. Neurobiol Dis. 2009; 37(1):13-25. DOI: 10.1016/j.nbd.2009.07.030. View

Metro G, Lunardi G, Floridi P, Pascali J, Marcomigni L, Chiari R . CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment. J Thorac Oncol. 2015; 10(5):e26-e27. DOI: 10.1097/JTO.0000000000000468. View

Kim D, Mehra R, Tan D, Felip E, Chow L, Camidge D . Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016; 17(4):452-463. PMC: 5063047. DOI: 10.1016/S1470-2045(15)00614-2. View

Johung K, Yeh N, Desai N, Williams T, Lautenschlaeger T, Arvold N . Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J Clin Oncol. 2015; 34(2):123-9. PMC: 5070549. DOI: 10.1200/JCO.2015.62.0138. View

Jiang J, Zhao C, Zhang F, Liu Z, Zhou K, Ren X . ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis. BMJ Open. 2022; 12(9):e060782. PMC: 9486327. DOI: 10.1136/bmjopen-2022-060782. View

Silverman J . Multidrug-resistance transporters. Pharm Biotechnol. 2000; 12:353-86. DOI: 10.1007/0-306-46812-3_13. View

Sun S, Pithavala Y, Martini J, Chen J . Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition. J Clin Pharmacol. 2022; 62(9):1170-1176. PMC: 9542378. DOI: 10.1002/jcph.2056. View

Daneman R . The blood-brain barrier in health and disease. Ann Neurol. 2013; 72(5):648-72. DOI: 10.1002/ana.23648. View

10.

Hiya S, Fujiwara S, Nakagawa A, Sato Y, Omura Y, Hara S . Isolated progression of miliary brain metastasis in a patient with stable lung adenocarcinoma successfully treated with whole-brain radiotherapy: A case report. eNeurologicalSci. 2021; 25:100366. PMC: 8413885. DOI: 10.1016/j.ensci.2021.100366. View

11.

Fromm M . P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000; 38(2):69-74. DOI: 10.5414/cpp38069. View

12.

Soria J, Tan D, Chiari R, Wu Y, Paz-Ares L, Wolf J . First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017; 389(10072):917-929. DOI: 10.1016/S0140-6736(17)30123-X. View

13.

Costa D, Kobayashi S, Pandya S, Yeo W, Shen Z, Tan W . CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011; 29(15):e443-5. DOI: 10.1200/JCO.2010.34.1313. View

14.

Shaw A, Felip E, Bauer T, Besse B, Navarro A, Postel-Vinay S . Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017; 18(12):1590-1599. PMC: 5777233. DOI: 10.1016/S1470-2045(17)30680-0. View

15.

Ningaraj N, Rao M, Hashizume K, Asotra K, Black K . Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther. 2002; 301(3):838-51. DOI: 10.1124/jpet.301.3.838. View

16.

Kort A, Sparidans R, Wagenaar E, Beijnen J, Schinkel A . Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacol Res. 2015; 102:200-7. DOI: 10.1016/j.phrs.2015.09.003. View

17.

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

18.

Loscher W, Potschka H . Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005; 2(1):86-98. PMC: 539326. DOI: 10.1602/neurorx.2.1.86. View

19.

Percy D, Ribot E, Chen Y, McFadden C, Simedrea C, Steeg P . In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol. 2011; 46(11):718-25. PMC: 7465076. DOI: 10.1097/RLI.0b013e318226c427. View

20.

Chow L, Barlesi F, Bertino E, van den Bent M, Wakelee H, Wen P . ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clin Cancer Res. 2022; 28(12):2506-2516. DOI: 10.1158/1078-0432.CCR-21-1838. View